Literature DB >> 19208853

Glucagon-mediated impairments in hepatic and peripheral tissue nutrient disposal are not aggravated by increased lipid availability.

Sheng-Song Chen1, Tammy S Santomango, Phillip E Williams, D Brooks Lacy, Owen P McGuinness.   

Abstract

Glucose, fat, and glucagon availability are increased in diabetes. The normal response of the liver to chronic increases in glucose availability is to adapt to become a marked consumer of glucose. Yet this fails to occur in diabetes. The aim was to determine whether increased glucagon and lipid interact to impair the adaptation to increased glucose availability. Chronically catheterized well controlled depancreatized conscious dogs (n = 21) received 3 days of continuous parenteral nutrition (TPN) that was either high in glucose [C; 75% nonprotein calories (NPC)] or in lipid (HL; 75% NPC) in the presence or absence of a low dose (one-third basal) chronic intraportal infusion of glucagon (GN; 0.25 ng.kg(-1).min(-1)). During the 3 days of TPN, all groups received the same insulin algorithm; the total amount of glucose infused (GIR) was varied to maintain isoglycemia ( approximately 120 mg/dl). On day 3 of TPN, hepatic metabolism was assessed. Glucose and insulin levels were similar in all groups. GIR was decreased in HL and C + GN ( approximately 30%) and was further decreased in HL + GN (55%). Net hepatic glucose uptake was decreased approximately 15% in C + GN, and HL and was decreased approximately 50% in HL + GN. Lipid alone or combined with glucagon decreased glucose uptake by peripheral tissues. Despite impairing whole body glucose utilization, HL did not limit whole body energy disposal. In contrast, glucagon suppressed whole body energy disposal irrespective of the diet composition. In summary, failure to appropriately suppress glucagon secretion adds to the dietary fat-induced impairment in both hepatic and peripheral glucose disposal. In addition, unlike increasing the percentage of calories as fat, inappropriate glucagon secretion in the absence of compensatory hyperinsulinemia limits whole body nutrient disposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208853      PMCID: PMC2681308          DOI: 10.1152/ajpendo.90821.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  33 in total

1.  High-fat/low-carbohydrate diet reduces insulin-stimulated carbohydrate oxidation but stimulates nonoxidative glucose disposal in humans: An important role for skeletal muscle pyruvate dehydrogenase kinase 4.

Authors:  K Chokkalingam; K Jewell; L Norton; J Littlewood; L J C van Loon; P Mansell; I A Macdonald; K Tsintzas
Journal:  J Clin Endocrinol Metab       Date:  2006-10-24       Impact factor: 5.958

2.  Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.

Authors:  Mandeep Bajaj; Swangjit Suraamornkul; Anthony Romanelli; Gary W Cline; Lawrence J Mandarino; Gerald I Shulman; Ralph A DeFronzo
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

3.  The effect of an acute elevation of NEFA concentrations on glucagon-stimulated hepatic glucose output.

Authors:  Carrie Everett-Grueter; Dale S Edgerton; E Patrick Donahue; Suzan Vaughan; Chang An Chu; Dana K Sindelar; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-04-11       Impact factor: 4.310

4.  Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia.

Authors:  S L Conarello; G Jiang; J Mu; Z Li; J Woods; E Zycband; J Ronan; F Liu; R Sinha Roy; L Zhu; M J Charron; B B Zhang
Journal:  Diabetologia       Date:  2006-11-28       Impact factor: 10.122

5.  Glucagon chronically impairs hepatic and muscle glucose disposal.

Authors:  Sheng-Song Chen; Yiqun Zhang; Tammy S Santomango; Phillip E Williams; D Brooks Lacy; Owen P McGuinness
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-11-28       Impact factor: 4.310

6.  Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration.

Authors:  Mandeep Bajaj; Rafael Medina-Navarro; Swangjit Suraamornkul; Christian Meyer; Ralph A DeFronzo; Lawrence J Mandarino
Journal:  Diabetes       Date:  2007-03       Impact factor: 9.461

7.  Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.

Authors:  Hans J Woerle; Ervin Szoke; Christian Meyer; Jean M Dostou; Steven D Wittlin; Niyaz R Gosmanov; Stephen L Welle; John E Gerich
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-08-16       Impact factor: 4.310

8.  Time course of the hepatic adaptation to TPN: interaction with glycogen depletion.

Authors:  Sheng-Song Chen; Carlos J Torres-Sanchez; Nadeen Hosein; Yiqun Zhang; D Brooks Lacy; Owen P McGuinness
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-31       Impact factor: 4.310

9.  PREPARATION OF FATTY ACID METHYL ESTERS AND DIMETHYLACETALS FROM LIPIDS WITH BORON FLUORIDE--METHANOL.

Authors:  W R MORRISON; L M SMITH
Journal:  J Lipid Res       Date:  1964-10       Impact factor: 5.922

10.  Dose-response effects of free fatty acids on glucose and lipid metabolism during somatostatin blockade of growth hormone and insulin in humans.

Authors:  L C Gormsen; N Jessen; J Gjedsted; S Gjedde; H Nørrelund; S Lund; J S Christiansen; S Nielsen; O Schmitz; N Møller
Journal:  J Clin Endocrinol Metab       Date:  2007-03-06       Impact factor: 5.958

View more
  3 in total

Review 1.  Physiologic action of glucagon on liver glucose metabolism.

Authors:  C J Ramnanan; D S Edgerton; G Kraft; A D Cherrington
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

2.  Continuous low-dose fructose infusion does not reverse glucagon-mediated decrease in hepatic glucose utilization.

Authors:  Paulette M Johnson; Sheng-Song Chen; Tammy S Santomango; Phillip E Williams; D Brooks Lacy; Owen P McGuinness
Journal:  Metabolism       Date:  2010-10-12       Impact factor: 8.694

3.  Glucagon as a critical factor in the pathology of diabetes.

Authors:  Dale S Edgerton; Alan D Cherrington
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.